Status:

COMPLETED

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

MALE

21-50 years

Phase:

PHASE1

Brief Summary

To assess the pharmacokinetics of midazolam with/without concomitant administration of crobenetine

Eligibility Criteria

Inclusion

  • \- All participants in the study should be healthy males, range from 21 to 50 years of age and their bodymass index (BMI) be within 18.5 to 29.9 kg/m2

Exclusion

  • Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy), which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study (except substitution therapy regarding thyroid gland)
  • Use of any drugs that might influence the results of the trial (within one week prior to administration or during the trial)
  • Participation in another trial with an investigational drug (within two months prior to administration or during the trial)
  • Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (\> 60 g/day)
  • Drug abuse
  • Blood donation (≥ 100 mL, within four weeks prior to administration or during the trial)
  • Excessive physical activities (within the last week before the study)
  • Any laboratory value outside the reference range of clinical relevance

Key Trial Info

Start Date :

February 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT02269202

Start Date

February 1 2002

Last Update

October 21 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.